1
|
Orso F, Virga F, Dettori D, Dalmasso A, Paradzik M, Savino A, Pomatto MAC, Quirico L, Cucinelli S, Coco M, Mareschi K, Fagioli F, Salmena L, Camussi G, Provero P, Poli V, Mazzone M, Pandolfi PP, Taverna D. Stroma-derived miR-214 coordinates tumor dissemination. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2023; 42:20. [PMID: 36639824 PMCID: PMC9837925 DOI: 10.1186/s13046-022-02553-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 11/29/2022] [Indexed: 01/15/2023]
Abstract
BACKGROUND Tumor progression is based on a close interaction between cancer cells and Tumor MicroEnvironment (TME). Here, we focus on the role that Cancer Associated Fibroblasts (CAFs), Mesenchymal Stem Cells (MSCs) and microRNAs (miRs) play in breast cancer and melanoma malignancy. METHODS We used public databases to investigate miR-214 expression in the stroma compartment of primary human samples and evaluated tumor formation and dissemination following tumor cell injections in miR-214 overexpressing (miR-214over) and knock out (miR-214ko) mice. In addition, we dissected the impact of Conditioned Medium (CM) or Extracellular Vesicles (EVs) derived from miR-214-rich or depleted stroma cells on cell metastatic traits. RESULTS We evidence that the expression of miR-214 in human cancer or metastasis samples mostly correlates with stroma components and, in particular, with CAFs and MSCs. We present data revealing that the injection of tumor cells in miR-214over mice leads to increased extravasation and metastasis formation. In line, treatment of cancer cells with CM or EVs derived from miR-214-enriched stroma cells potentiate cancer cell migration/invasion in vitro. Conversely, dissemination from tumors grown in miR-214ko mice is impaired and metastatic traits significantly decreased when CM or EVs from miR-214-depleted stroma cells are used to treat cells in culture. Instead, extravasation and metastasis formation are fully re-established when miR-214ko mice are pretreated with miR-214-rich EVs of stroma origin. Mechanistically, we also show that tumor cells are able to induce miR-214 production in stroma cells, following the activation of IL-6/STAT3 signaling, which is then released via EVs subsequently up-taken by cancer cells. Here, a miR-214-dependent pro-metastatic program becomes activated. CONCLUSIONS Our findings highlight the relevance of stroma-derived miR-214 and its release in EVs for tumor dissemination, which paves the way for miR-214-based therapeutic interventions targeting not only tumor cells but also the TME.
Collapse
Affiliation(s)
- Francesca Orso
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy ,grid.16563.370000000121663741Dept. of Translational Medicine (DIMET), Università del Piemonte Orientale, Novara, Italy
| | - Federico Virga
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy ,grid.11486.3a0000000104788040Lab of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Louvain, Belgium ,grid.467824.b0000 0001 0125 7682Present Address: Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Daniela Dettori
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Alberto Dalmasso
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Mladen Paradzik
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Aurora Savino
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | | | - Lorena Quirico
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Stefania Cucinelli
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Martina Coco
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Katia Mareschi
- grid.415778.80000 0004 5960 9283Paediatric Onco-Haematology Division, Regina Margherita Children’s Hospital, City of Health and Science of Turin, Turin, Italy ,grid.7605.40000 0001 2336 6580Department of Public Health and Paediatrics, University of Turin, Turin, Italy
| | - Franca Fagioli
- grid.415778.80000 0004 5960 9283Paediatric Onco-Haematology Division, Regina Margherita Children’s Hospital, City of Health and Science of Turin, Turin, Italy ,grid.7605.40000 0001 2336 6580Department of Public Health and Paediatrics, University of Turin, Turin, Italy
| | - Leonardo Salmena
- grid.231844.80000 0004 0474 0428Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Giovanni Camussi
- grid.7605.40000 0001 2336 6580Department of Medical Sciences, University of Turin, Turin, Italy
| | - Paolo Provero
- grid.18887.3e0000000417581884Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy ,grid.7605.40000 0001 2336 6580Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Turin, Italy
| | - Valeria Poli
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| | - Massimiliano Mazzone
- grid.11486.3a0000000104788040Lab of Tumor Inflammation and Angiogenesis, Center for Cancer Biology (CCB), VIB, Louvain, Belgium
| | - Pier Paolo Pandolfi
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy ,grid.298261.60000 0000 8685 5368William N. Pennington Cancer Institute, Renown Health, Nevada System of Higher Education, Reno, NV 89502 USA
| | - Daniela Taverna
- Molecular Biotechnology Center (MBC) “Guido Tarone”, Via Nizza, 52, 10126 Turin, Italy ,grid.7605.40000 0001 2336 6580Dept. Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza, 52, 10126 Turin, Italy
| |
Collapse
|
6
|
Biadasiewicz K, Sonderegger S, Haslinger P, Haider S, Saleh L, Fiala C, Pollheimer J, Knöfler M. Transcription factor AP-2α promotes EGF-dependent invasion of human trophoblast. Endocrinology 2011; 152:1458-69. [PMID: 21303946 DOI: 10.1210/en.2010-0936] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The basic helix-span-helix transcription factor activating protein (AP)-2α is critically involved in cell-specific hormone expression of syncytializing human trophoblasts. Its role in invasive trophoblast differentiation, however, remains largely elusive. Using RT-PCR, Western blotting, and immunofluorescence of first-trimester placentae, we here show that AP-2α is expressed in extravillous trophoblasts (EVTs) both in situ and in vitro as well as in invasive trophoblast cell lines. Its protein expression was increased upon supplementation of epidermal growth factor (EGF) both in primary EVTs and trophoblastic SGHPL-5 cells. Gene silencing of AP-2α using small hairpin microRNA (shRNAmir) did not affect basal invasion of SGHPL-5 cells through Matrigel-coated filters but reduced EGF-stimulated invasion. Similarly, treatment of primary EVTs with AP-2α small interfering RNA decreased EGF-dependent invasion. Proliferation of SGHPL-5 cells and primary EVTs, measured by cumulative cell numbers and 5-bromo-2'-deoxyuridine labeling, respectively, were not affected on loss of AP-2α. EGF-dependent induction of matrix metalloproteinase (MMP)-2, pro- and active form of urokinase plasminogen activator, and chorionic gonadotropin (CG)-β was noticed in shRNAmir-control cells, whereas these genes were suppressed in EGF-treated shRNAmir-AP-2α cells. Similarly, EGF-stimulated MMP-2 and CGβ protein expression was reduced in AP-2α small interfering RNA-treated primary EVTs. Knockdown of AP-2α also decreased luciferase activity of the CGβ5 promoter in SGHPL-5 cells, which was compensated upon transient overexpression of AP-2α cDNA. In conclusion, we show that AP-2α expression positively affects human trophoblast invasion under EGF-stimulated conditions, likely by inducing critical invasion-promoting genes such MMP-2, urokinase plasminogen activator, and CG.
Collapse
Affiliation(s)
- Katarzyna Biadasiewicz
- Department of Obstetrics and Fetal-Maternal Medicine, Reproductive Biology Unit, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|